JP2012522783A5 - - Google Patents

Info

Publication number

JP2012522783A5

JP2012522783A5 JP2012503429A JP2012503429A JP2012522783A5 JP 2012522783 A5 JP2012522783 A5 JP 2012522783A5 JP 2012503429 A JP2012503429 A JP 2012503429A JP 2012503429 A JP2012503429 A JP 2012503429A JP 2012522783 A5 JP2012522783 A5 JP 2012522783A5

Authority

JP

Japan

Prior art keywords

pharmaceutical composition

item

composition according

nasal cavity

subject

Prior art date

2010-04-02

Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)

Granted

Links

• Espacenet
• Global Dossier
• Discuss

• 239000008194 pharmaceutical composition Substances 0.000 claims description 87
• 239000000203 mixture Substances 0.000 claims description 21
• 210000003928 nasal cavity Anatomy 0.000 claims description 18
• 210000001519 tissue Anatomy 0.000 claims description 14
• WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical group OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 12
• WYWIFABBXFUGLM-UHFFFAOYSA-N oxymetazoline Chemical group CC1=CC(C(C)(C)C)=C(O)C(C)=C1CC1=NCCN1 WYWIFABBXFUGLM-UHFFFAOYSA-N 0.000 claims description 12
• GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 claims description 10
• 229960002372 tetracaine Drugs 0.000 claims description 10
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 9
• 210000004228 maxillary nerve Anatomy 0.000 claims description 8
• 210000003254 palate Anatomy 0.000 claims description 8
• 239000003755 preservative agent Substances 0.000 claims description 8
• 230000002335 preservative effect Effects 0.000 claims description 8
• 239000007921 spray Substances 0.000 claims description 8
• 239000002562 thickening agent Substances 0.000 claims description 8
• 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 6
• 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 6
• 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 6
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 claims description 6
• 229960001528 oxymetazoline Drugs 0.000 claims description 6
• 239000002245 particle Substances 0.000 claims description 6
• 150000003839 salts Chemical class 0.000 claims description 6
• 239000005526 vasoconstrictor agent Substances 0.000 claims description 6
• CFKMVGJGLGKFKI-UHFFFAOYSA-N 4-chloro-m-cresol Chemical compound CC1=CC(O)=CC=C1Cl CFKMVGJGLGKFKI-UHFFFAOYSA-N 0.000 claims description 4
• 208000003098 Ganglion Cysts Diseases 0.000 claims description 4
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
• ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 4
• 208000005400 Synovial Cyst Diseases 0.000 claims description 4
• 239000000384 adrenergic alpha-2 receptor agonist Substances 0.000 claims description 4
• 235000019445 benzyl alcohol Nutrition 0.000 claims description 4
• 239000003937 drug carrier Substances 0.000 claims description 4
• 150000005846 sugar alcohols Chemical class 0.000 claims description 3
• NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 claims description 2
• QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 claims description 2
• QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 claims description 2
• RCEFMOGVOYEGJN-UHFFFAOYSA-N 3-(2-hydroxyphenyl)-6-(3-nitrophenyl)-1,4-dihydropyrimidin-2-one Chemical compound OC1=CC=CC=C1N1C(=O)NC(C=2C=C(C=CC=2)[N+]([O-])=O)=CC1 RCEFMOGVOYEGJN-UHFFFAOYSA-N 0.000 claims description 2
• 229940127291 Calcium channel antagonist Drugs 0.000 claims description 2
• 102000018899 Glutamate Receptors Human genes 0.000 claims description 2
• 108010027915 Glutamate Receptors Proteins 0.000 claims description 2
• XADCESSVHJOZHK-UHFFFAOYSA-N Meperidine Chemical compound C=1C=CC=CC=1C1(C(=O)OCC)CCN(C)CC1 XADCESSVHJOZHK-UHFFFAOYSA-N 0.000 claims description 2
• 102100024304 Protachykinin-1 Human genes 0.000 claims description 2
• 101800003906 Substance P Proteins 0.000 claims description 2
• 239000000533 adrenergic alpha-1 receptor agonist Substances 0.000 claims description 2
• 239000000480 calcium channel blocker Substances 0.000 claims description 2
• 239000003795 chemical substances by application Substances 0.000 claims description 2
• 229960002242 chlorocresol Drugs 0.000 claims description 2
• 229930003836 cresol Natural products 0.000 claims description 2
• 210000002455 dental arch Anatomy 0.000 claims description 2
• 229940079593 drug Drugs 0.000 claims description 2
• 239000003814 drug Substances 0.000 claims description 2
• 210000000981 epithelium Anatomy 0.000 claims description 2
• 230000001815 facial effect Effects 0.000 claims description 2
• 239000000017 hydrogel Substances 0.000 claims description 2
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
• UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
• MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 claims description 2
• 239000003112 inhibitor Substances 0.000 claims description 2
• 239000003446 ligand Substances 0.000 claims description 2
• 210000004086 maxillary sinus Anatomy 0.000 claims description 2
• 229920000609 methyl cellulose Polymers 0.000 claims description 2
• 239000001923 methylcellulose Substances 0.000 claims description 2
• 210000004400 mucous membrane Anatomy 0.000 claims description 2
• 210000005036 nerve Anatomy 0.000 claims description 2
• 210000000929 nociceptor Anatomy 0.000 claims description 2
• 108091008700 nociceptors Proteins 0.000 claims description 2
• 210000000056 organ Anatomy 0.000 claims description 2
• 229960000482 pethidine Drugs 0.000 claims description 2
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims description 2
• 206010002091 Anaesthesia Diseases 0.000 claims 1
• 230000037005 anaesthesia Effects 0.000 claims 1
• 238000000034 method Methods 0.000 description 17
• 238000005507 spraying Methods 0.000 description 3
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
• 235000010981 methylcellulose Nutrition 0.000 description 1
• 238000002663 nebulization Methods 0.000 description 1
• 239000000779 smoke Substances 0.000 description 1